PerkinElmer (Waltham, MA) has entered into an agreement to acquire BioLegend (San Diego, CA), a provider of life science antibodies and reagents, for approximately $5.25 billion, subject to certain adjustments.
BioLegend provides its academic and biopharmaceutical customers with antibodies and reagents in high-growth areas such as cytometry, proteogenomics, multiplex assays, recombinant proteins, magnetic cell separation, and bioprocessing. The transaction will be the largest in PerkinElmer’s history and is expected to close by the end of the 2021 calendar year, subject to regulatory approvals and other customary closing conditions.
BioLegend has more than 700 employees based primarily in the U.S., with estimated 2022 revenues of $380 million. Upon joining PerkinElmer, BioLegend will expand PerkinElmer’s existing life science franchise into new segments, and its campus in San Diego will become PerkinElmer’s global Center of Excellence (CoE) for research reagent content development for the combined company.